TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12030615
Drug: Dexamethasone administration
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone administration at 21:00 h vs 23:00 h
Study: 367255
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (Resibion) 500 mg
Study: 367255
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (Resibion) 250 mg every 6 hours
Study: 367255
Drug: Enteric-coated erythromycin
Normalized name: erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated erythromycin base (Etromycin) 250 mg every 6 hours
Study: 24733648
Drug: Physiotherapy added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy added to standard treatment (deep breathing exercises, mobilizations, incentive spirometry)
Study: 24733648
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (medical treatment and drainage)
Study: 20819541
Drug: Sucrose gel
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose gel
Study: 16466166
Drug: Fuzheng Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huayu Capsule (FHC)
Study: 9055715
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily for eight weeks plus amoxycillin 750 mg twice daily for weeks 7 and 8
Study: 8396084
Drug: Dicloxacillin 250
Normalized name: dicloxacillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin 250 mg four times a day for seven days
Study: 3729711
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin sodium and metronidazole
Study: 3729711
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G sodium, streptomycin, and metronidazole
Study: 29407540
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus exercise (S+EX)
Study: 29407540
Drug: Sertraline (S)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (S)
Study: 25204412
Drug: Chemoradiation group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation group (additional radiotherapy, second-line chemotherapy, or both)
Study: 22288725
Drug: Low-dose azithromycin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azithromycin (250 mg orally daily for 5 days then 2× weekly for a total of 12 weeks)
Study: 18551087
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise and hormone therapy (estradiol valerate 1 mg/d orally)
Study: 18551087
Drug: Sedentary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedentary and hormone therapy (estradiol valerate 1 mg/d orally)
Study: 16083524
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 100 mg/kg into the cardiopulmonary bypass prime followed by infusion at 20 mg/kg/h
Study: 7913854
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg propranolol (PR)
Study: 42577
Drug: Buccal tablets
Normalized name: Acyclovir Buccal Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal tablets of demoxytocin
Study: 26093675
Drug: Standard directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard directly observed treatment strategy (control).
Study: 23629959
Drug: CBT‐I with
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT‐I with adjunctive IRT
Study: 20401752
Drug: Enzymatic hydrolysed
Normalized name: hydrolysed marine collagen (enzymatic; 2000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatic hydrolysed collagen (EHC) 10 g daily
Study: 20401752
Drug: Glucosamine sulphate
Normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulphate (GS) 1.5 g
Study: 12790943
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment (Group A)
Study: 12790943
Drug: Closed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed treatment (Group B)
Study: 9727544
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (ISMN, 50 mg once daily)
Study: 7519764
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg panomifene (PAN)
Study: 7519764
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg panomifene (PAN)
Study: 7519764
Drug: FSH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSH and LH (both doses)
Study: 3191339
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin (control)
Study: 31691723
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (500 mg tablet per day)
Study: 27825697
Drug: Infusional 5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusional 5‐fluorouracil (FU) chemotherapy
Study: 27825697
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with irinotecan (IRI)
Study: 27825697
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy (FU + IRI)
Study: 23510513
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate (CaP) supplementation (plus 1 g calcium/d)
Study: 21216868
Drug: ChimeriVax-WN02 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChimeriVax-WN02 vaccine
Study: 18647268
Drug: Spicy meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spicy meal (standard meal mixed with 2 g chili)
Study: 18647268
Drug: Standard meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard meal with 2 g chili in capsules
Study: 18647268
Drug: Standard meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard meal with chili capsules
Study: 9601160
Drug: Ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 800 mg/day
Study: 9601160
Drug: Codeine 120
Normalized name: TY-PAP with Codeine 120mg-12mg/5ml Elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine 120 mg/day
Study: 8056992
Drug: Moclobemide (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (450 mg daily)
Study: 8056992
Drug: Imipramine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (150 mg daily)
Study: 2658581
Drug: Ciprofloxacin 750
Normalized name: ciprofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 750 mg or 1,000 mg twice daily
Study: 23456769
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 200 μg for 12 weeks
Study: 23456769
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 μg for 12 weeks
Study: 23456769
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 μg compared to 200 μg
Study: 23456769
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 μg compared to 0 μg
Study: 23456769
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 μg
Study: 17105658
Drug: Primaquine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primaquine (45 mg single dose)
Study: 11398582
Drug: Divina (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divina (2 mg valerate estradiol and 10 mg medroxyprogesterone acetate)
Study: 9267584
Drug: Trace elements/zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trace elements/zinc 20 mg
Study: 9267584
Drug: Vitamins (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins (vitamin C 120 mg; beta‐carotene 6 mg; alpha‐tocopherol 15 mg)
Study: 9267584
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trace elements and vitamins at equal doses
Study: 8453855
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg every day)
Study: 3087688
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 1 mg nitroglycerin
Study: 29505804
Drug: Optimal antidepressant
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal antidepressant monotherapy (imipramine or venlafaxine) for 7 weeks
Study: 29505804
Drug: Subsequent plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent plasma level-targeted dose lithium addition for 4 weeks
Study: 29505804
Drug: Subsequent electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent electroconvulsive therapy
Study: 22431703
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment plus RFA
Study: 1353540
Drug: Buserelin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (20 micrograms, administered daily in a nasal spray)
Study: 1353540
Drug: Human chorionic
Normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human chorionic gonadotropin (administered after buserelin treatment)
Study: 24687848
Drug: Optimally dosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimally dosed medication
Study: 18597078
Drug: Bifeprunox 20
Normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifeprunox 20 mg
Study: 18597078
Drug: Bifeprunox (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifeprunox (5 mg, 10 mg)
Study: 18597078
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg
Study: 16021194
Drug: Oral diazepam,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam, mefenamic acid, acetaminophen (alone or in combination)
Study: 16021194
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of ketorolac tromethamine
Study: 14508365
Drug: Itraconazole (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (5.0 mg/kg orally, preoperatively, 2.5 mg/kg orally, two times a day, postoperatively)
Study: 10961161
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg three times per day)
Study: 8672323
Drug: 10% low‐molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% low‐molecular weight (LMW) hydroxyethylstarch solution (HES) in sepsis patients
Study: 8672323
Drug: 10% low‐molecular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% low‐molecular weight (LMW) hydroxyethylstarch solution (HES) in trauma patients
Study: 2666205
Drug: benztropine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: benztropine (mean dose 3.8 mg)
Study: 14602
Drug: Propoxyphene napsylate
Normalized name: Propoxyphene Napsylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propoxyphene napsylate at maximum doses
Study: 26460660
Drug: Methylprednisolone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (250 mg at anaesthetic induction and 250 mg at initiation of cardiopulmonary bypass)
Study: 18296556
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg oral granules
Study: 18296556
Drug: Montelukast 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 8 mg once daily for 7 days
Study: 18296556
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 mg once daily for 7 days
Study: 14739625
Drug: Aspirin combined
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin combined with heparin
Study: 14739625
Drug: Aspirin combined
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin combined with heparin and ultrasound
Study: 14739625
Drug: Eptifibatide combined
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide combined with aspirin, heparin, and ultrasound
Study: 14739625
Drug: Tirofiban combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban combined with aspirin, heparin, and ultrasound
Study: 10958091
Drug: 3 microg
Normalized name: Calcitriol 3 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 microg x kg(‐1) oral clonidine
Study: 8769388
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 micrograms subcutaneously three times daily for 3 to 6 weeks before surgery (group 1)
Study: 8769388
Drug: Octreotide 100
Normalized name: 1 ML octreotide 100 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 100 micrograms subcutaneously three times daily for 3 to 9 months (group 2)
Study: 8769388
Drug: Octreotide 500
Normalized name: 1 ML octreotide 500 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 500 micrograms subcutaneously three times daily (increased dose for incomplete suppression in group 2)
Study: 8446671
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 1 mg/kg body weight
Study: 8446671
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 2 mg/kg body weight
Study: 8446671
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 3 mg/kg body weight
Study: 8446671
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 4 mg/kg body weight
Study: 2946644
Drug: Procaterol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol (20 mcg)
Study: 2946644
Drug: Salbutamol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (200 mcg)
Study: 25218600
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg/d after 1 month of titration)
Study: 19888921
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg (2.5 mg for <6 years)
Study: 18716362
Drug: Azelnidipine (AZ)
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (AZ) 16 mg/d
Study: 18716362
Drug: Nifedipine-CR (NF)
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine-CR (NF) 40 mg/d
Study: 1836066
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist isradipine
Study: 28668229
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of probiotics for three weeks or until they gave birth
Study: 19436282
Drug: AST-120 (spherical
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (spherical carbon adsorbent) 2-g sachets, oral, thrice a day for 4 weeks
Study: 17370490
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with medicine
Study: 15505150
Drug: AVP-923 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP-923 (30 mg of DM plus 30 mg of Q) given twice daily for 28 days
Study: 11218745
Drug: Super-high-flow injection
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-high-flow injection method (Group A)
Study: 11218745
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection method (Group B)
Study: 27842707
Drug: Propofol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.2 mg.kg-1 followed by infusion at a rate of 2 mg.kg-1.h-1
Study: 27842707
Drug: Ketamine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine continuous infusion at 0.5 mg.kg-1.h-1
Study: 19925721
Drug: Night-time sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time sleep facilitating cereal (225 mg tryptophan, 5.3 mg adenosine‐5'‐P, 6.3 mg uridine‐5'‐P per 100 g)
Study: 19925721
Drug: Night-time sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time sleep facilitating cereal with enriched night milk (480 mg tryptophan, 8.8 mg uridine‐5'‐P, 7.6 mg adenosine‐5'‐P per 100 g)
Study: 19925721
Drug: Standard cereal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cereal (75 mg tryptophan/100 g product without nucleotides)
Study: 16516851
Drug: Monocytes from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocytes from volunteers with -137G/G genotype
Study: 9346455
Drug: Self-administered previsit
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered previsit questionnaire
Study: 29680419
Drug: Green Bright
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Bright Light Therapy (∼507 nm) and Sedentary Activity (sitting, watching TV)
Study: 29680419
Drug: Green Bright
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Bright Light Therapy (∼507 nm) and Morning Activity (standing, playing motion-sensing videogame)
Study: 29680419
Drug: Red Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Light Therapy (∼643 nm) and Sedentary Activity (sitting, watching TV)
Study: 29680419
Drug: Red Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Light Therapy (∼643 nm) and Morning Activity
Study: 24997005
Drug: EPA-rich oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich oil capsules
Study: 24997005
Drug: DHA-rich oil
Normalized name: Ulkenia DHA oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-rich oil capsules
Study: 2173168
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (1 x 1.500 aPTT units plus 2 x placebo injections)
Study: 2173168
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose conventional heparin (3 x 5.000 IU)
Study: 2173168
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose conventional heparin
Study: 699483
Drug: Diazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (30 mg) injected intravenously during uterine contractions (Group I)
Study: 699483
Drug: Diazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (30 mg) injected intravenously in the relaxation period (Group II)
Study: 30739558
Drug: Sequential strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential strategy (LV5FU2 followed by FOLFOX6)
Study: 30739558
Drug: Combination strategy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination strategy (FOLFOX6 followed by FOLFIRI)
Study: 26390700
Drug: 252Cf neutron
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 252Cf neutron brachytherapy (700‐800 cGy doses at point A, once a week)
Study: 26390700
Drug: Neoadjuvant intra‐arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant intra‐arterial embolism chemotherapy (bleomycin, carboplatin, and cyclophosphamide, twice)
Study: 15713722
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg nandrolone decanoate
Study: 15713722
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nandrolone decanoate
Study: 15713722
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg nandrolone decanoate
Study: 11921498
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg metadoxine (given intravenously) added to standard treatment
Study: 9055913
Drug: Growth-promoting treatment
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth-promoting treatment
Study: 7033015
Drug: Flurbiprofen 100
Normalized name: flurbiprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 100 mg suppository
Study: 22419369
Drug: rhPTH (1‐34)
Normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rhPTH (1‐34) (20 μg, once-daily subcutaneous injection)
Study: 22419369
Drug: elcatonin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: elcatonin (200 U, once-weekly intramuscular injection)
Study: 19585577
Drug: Homozygous G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homozygous G allele genotype
Study: 19585577
Drug: G allele
Approvals — FDA: no, EMA: no, PMDA: no
Description: G allele
Study: 15381586
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous access
Study: 10518849
Drug: Herbal Toothpaste
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal Toothpaste and Gum Therapy
Study: 8125413
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Parlodel SRO
Study: 8125413
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg Parlodel b.i.d.
Study: 8125413
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Parlodel SRO (single dose)
Study: 8125413
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Parlodel (two doses of 5 mg)
Study: 70149
Drug: Prednisolone (maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (maintenance dose 15 mg/day)